aod9604 igf 1 levels AOD-9604 Peptide AOD-9604 Fat Loss Treatment in
Description
This choice reflects stability considerations
The clinical drug development program was halted in 2007 after the pivotal Phase IIb trial did not show statistically significant weight loss in the primary endpoint
AOD-9604 is not FDA-approved as a drug
If you suspect you have experienced a side effect from any medicine or research chemical, you can report it to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk)
The timeline varies, but heres what most people experience: Within 2472 hours: A slight boost in energy or alertness
